Whole-Body Hyperthermia (WBH): Synergy in Oncology, Immunomodulation, and Clinical Evidence (wIRA)

Whole-Body Hyperthermia (WBH) in Oncology & Other Pathologies: Consolidated Synergy, Immunomodulation, and Clinical Evidence

Published: | Last Reviewed:

Whole-Body Hyperthermia (WBH) is a systemic oncological strategy that involves controlled heating of the body-core temperature, often using water-filtered Infrared-A (wIRA) technology. WBH is fundamentally a chemo/radio sensitizer, significantly improving tumor perfusion and oxygenation to amplify the effectiveness of traditional treatments. Crucially, it functions as a powerful systemic immunomodulator, mobilizing Heat Shock Proteins (HSPs) and T-cells, which creates essential synergy with cutting-edge Immunotherapy (ICI) and offers dramatic, rapid pain relief and Quality of Life improvement across various cancers and chronic pathologies like Fibromyalgia.

* Medical Disclaimer: This article is intended for informational purposes only and is not a substitute for individualized medical consultation, diagnosis, or treatment provided by a licensed physician.

1. Defining Whole-Body Hyperthermia (WBH) and Therapeutic Technology

Whole-Body Hyperthermia (WBH), or “systemic hyperthermia,” is defined as the controlled increase of the body-core temperature for therapeutic purposes. Based on the spectrum of effects of natural fever at different temperatures, WBH procedures are differentiated as follows:

  • • Mild WBH: < 38.5°C
  • • Moderate WBH: 38.5°C – 40.5°C
  • • Extreme WBH: > 40.5°C

Mild and moderate WBH in particular increases perfusion, stimulates the metabolism, reduces muscle tone, and stimulates the immune system.

The von Ardenne IRATHERM® 1000M WBH wIRA device uses exclusively skin-compatible, deep-tissue, water-filtered Infrared-A (wIRA) heat radiation (without IR-B / IR-C) for this purpose. Its non-claustrophobic, open system design ensures a uniform irradiation intensity over the entire patient (back) level and offers the user an optimal, patient-specific heat supply.

Water-filtered infrared-A radiation corresponds to the natural thermal radiation of the sun, providing the technological basis for uniform and gentle application of heat [1, 5, 7, 8].

Using the von Ardenne IRATHERM® principle, which has been proven for more than 30 years, Prof. Manfred von Ardenne has succeeded in reproducing this thermal radiation physically and technically, making it available for sustainable medical use in oncology and other pathologies.

von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-wIRA

2. Scientific Foundations and Systemic Effects

WBH has evolved into a strategy based on solid biophysical and physiological principles. In oncology, the focus is on Moderate and Fever-Range Hyperthermia (FR-WBH), recognized as treatments with multiple therapeutic indications [1, 3].

The technological basis for the uniform and gentle application of heat is often provided by devices using water-filtered Infrared-A (wIRA) radiation. Detailed biophysical studies have validated this technology’s ability to ensure deep and controlled heating, considering the optical properties of the skin and the photobiological basis for dosimetry [5, 7, 8].

At the physiological level, WBH has fundamental systemic effects:

  1. Improved Blood Rheology: Exposure to IR-WBH favorably influences blood flow properties and hemodynamics [2], supporting the essential mechanism of improving tumor perfusion—a critical precondition for the success of systemic treatments.
  2. General Biological Activation: WBH induces a thermal stress response that triggers a cascade of biological processes, including the modulation of the hormonal system and the acceleration of metabolism [6, 4].

Due to these foundations, WBH functions as a systemic immunomodulator, optimizing the tumor microenvironment (TME) and amplifying the effectiveness of cutting-edge oncological treatments [9].

3. Key Mechanisms of Action (Molecular, Physiological, and Immunological)

The therapeutic effects of WBH are complex, mediated by changes at the cellular, immune, and physiological levels:

A. Synergy with Chemotherapy and Radiotherapy (Chemo/Radio Sensitizer)

  • Optimization of the Tumor Microenvironment (TME): WBH improves tumor blood perfusion and oxygenation, reversing tumor hypoxia. This is essential, as well-oxygenated tumor cells are significantly more susceptible to destruction by Chemotherapy (CT) and Radiotherapy (RT) [9, 41].
  • Chemo/Radio Efficacy: Hyperthermia acts as a chemo & radio sensitizer, improving tumor oxygen supply (radio-sensitizing effect) & boosting the effectiveness of drugs like Cisplatin, Gemcitabine, and Carboplatin [12, 16, 36].

B. Inducing a Robust Anti-Tumor Immune Response (Immunomodulation)

WBH is a strong activator of the body’s defense system [11]:

  • Heat Shock Proteins (HSPs): Thermal stress stimulates the synthesis and release of HSP70. These proteins act as ‘danger signals’ that mark cancer cells for an enhanced attack by the immune system’s Cytotoxic T Lymphocytes (CTLs) [9, 10, 29].
  • Activation of Key Immune Cells: The 39–43°C temperature range increases the activity of Natural Killer (NK) cells and fosters the activity of helper and cytotoxic T cells, dendritic cells, and macrophages, while potentially compromising immunosuppressive cells [9, 10, 11, 25, 26].
  • T-Lymphocyte Increase: FR-WBH can significantly increase (e.g., 3-fold) the population of cytotoxic T lymphocytes in lymphoid organs, thereby enhancing the systemic anti-tumor immune attack [10].
  • Vaccines and APCs: WHT can regulate the function of Antigen-Presenting Cells (APCs) and increase the effectiveness of cancer vaccines, including those based on HSP110 and GRP170 [37, 28].

4. Clinical Evidence and Synergy in Multimodal Therapy

A. Synergy with Immunotherapy (Checkpoint Inhibitors – ICI)

A retrospective case series of 131 advanced (Stage IV) cancer patients investigated a multimodal protocol including whole body hyperthermia alongside checkpoint inhibitors (Ipilimumab, Nivolumab) and IL-2 [18].

Key Conclusion: wIRA Whole Body Hyperthermia was determined to be an integral and essential component that maximized the anti-tumor immune response.

WBH activates and mobilizes T cells (by inducing HSP70 and releasing tumor antigens); checkpoint inhibitors then “remove the brake” from these pre-activated T cells, resulting in unusually high favorable clinical response rates for advanced disease [18].

B. Clinical Applications in Various Cancers

  • Pancreatic Cancer: Phase I-II protocols using mild WBH (FR-WBH) combined with chemotherapy and Interferon-alpha showed at least 50% tumor regression in nearly half of the therapy-resistant patients [4, 22].
  • Breast Cancer (Recurrence): WHT combined with re-irradiation or radiotherapy has shown effectiveness for locally advanced breast cancer and chest wall recurrence, confirmed by randomized data [39, 40].
  • Ovarian Cancer: WBH combined with carboplatin was investigated in a Phase II study for recurrent ovarian cancer [16, 20].
  • Colorectal Cancer: WBH wIRA was used in the context of Von Ardenne’s Systemic Cancer Multistep Therapy (sCMT) combined with chemotherapy in a Phase I/II study [15].

5. Rapid Pain Relief and Significant Quality of Life (QoL) Improvement

Patients may experience rapid pain relief and a general improvement in well-being, as observed in Dr. Bull’s study [12] and especially in the more recent Phase III clinical study performed by Sahinbas et al. [14].

Clinical Insight:

wIRA therapy contributes not only to tumor control but also to a significant reduction in the need for analgesics, restoring mobility and vitality even in patients with advanced disease.

Phase III Clinical Trial (2024) for Bone Metastases

In 2024, Sahinbas and colleagues published a phase III study for bone metastases pain mainly from breast and prostate cancer using WBH wIRA Iratherm hyperthermia devices in addition to RT [14].

Key Findings: The radiotherapy (RT) alone group presented the most intense pain. The RT + WBH group showed a CR rate of 47.4% vs. 5.3% for RT alone within 2 months post-treatment.

The time to complete pain relief was just 10 days for the RT + WBH group, while the endpoint was not reached in the RT alone group.

QoL Indicator/Pain Improvement RT monotherapy RT + Hyperthermia (wIRA) Impact QoL
Complete Response Rate (CR) (2 months) 5.3 % 47.4 % +894% increase in chances of total pain elimination
Time to complete pain relief not reached 10 days “significant and rapid” benefit
Duration of Pain Relief Median: 28 days Median: Over 24 weeks Relief duration increases sixfold

Compared with the similar Phase III study published by Chi MS et al. (2017) with RF locoregional hyperthermia, the benefits achieved using WBH wIRA hyperthermia were far superior.

RF HT + RT Study Results (Local Hyperthermia):

QoL Indicator/Pain Improvement RT monotherapy RT + Hyperthermia (RF HT) Impact QoL
Complete Response Rate (CR) (3 Months) 7.1 % 37.9 % 533% increase in chances of total pain relief
Duration of Pain Relief Median: 55 days Median: Not reached at 24 weeks Duration of relief triples

Summary and Conclusion

The consolidated scientific evidence (from foundational studies on wIRA technology to crucial Phase III clinical trials) confirms WBH’s role as a multi-impact adjuvant therapy in oncology: it boosts CT/RT efficacy, activates the systemic immune system (including synergy with immunotherapy), and dramatically improves pain control and QoL for cancer patients.

6. Systemic Physiological Benefits and Therapeutic Potential in Other Pathologies

The gentle, controlled heat provided by WBH with wIRA radiation initiates complex thermoregulatory responses that yield broad systemic benefits, extending therapeutic potential beyond oncology:

A. Musculoskeletal and Pain Management

WBH is effective in managing chronic pain syndromes, leveraging its physiological effects on muscle tone and microcirculation:

  • Dorsalgia (Chronic Back Pain): Studies show that mild WBH, when combined with stationary multimodal pain therapy, provides significant benefit for patients with chronic non-specific low back pain [53, 54].
  • Fibromyalgia Syndrome (FMS): WBH is a documented adjunct treatment for FMS. Randomized controlled trials have demonstrated the effectiveness of mild wIRA WBH, showing effects on pain intensity and mental state [17, 56, 57].
  • Ankylosing Spondylitis (AS): WBH has shown immunomodulatory effects in AS patients, increasing anti-inflammatory mediators like Interleukin-10 (IL-10) and modulating pro-inflammatory cytokines like TNF-$α$ [58, 59, 52].
  • Raynaud’s Phenomenon in Systemic Sclerosis: Infrared-mediated hyperthermia has been found to be effective in treating vasoconstrictive symptoms, demonstrating clear vascular benefits [49].

B. Cardiovascular and Circulatory Health ❤️

Beyond improving tumor perfusion, WBH has specific effects on the circulatory system:

  • Essential Hypertension: A series of studies investigated the use of mild IR-A hyperthermia in patients with arterial hypertension (WHO Stages I and II). Findings indicate that serial treatments can positively affect central and peripheral pulse waves, blood pressure, and blood viscosity, confirming WBH’s role as a non-pharmacological physical therapy option [44, 47].

C. Neuro-Endocrine and Psychological Effects

WBH engages the body’s neuro-endocrine systems, influencing mood and metabolism:

  • Major Depressive Disorder (MDD): A randomized clinical trial demonstrated that a single session of WBH could act as a rapid-acting antidepressant, resulting in a reduction of depressive symptoms for several weeks. This effect is linked to the heat-induced activation of immune and inflammatory pathways that influence the brain [51].
  • Hormonal Modulation (Endocrinology): WBH stimulates the Hypothalamic-Pituitary-Adrenal (HPA) axis and influences hormone levels. Studies have documented responses of Growth Hormone and Prolactin during whole-body hyperthermia, highlighting its impact on endocrine regulation [42, 43].
  • Metabolism and Cell Reaction: WBH accelerates the basal metabolic rate. At the cellular level, heat influences pO2 kinetics and is linked to the synthesis of protective proteins like ferritin in the skin, supporting tissue repair [48, 46].
von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-summary

Frequently Asked Questions (FAQ) on Recommended WBH Sessions and Target Temperatures

Treatments shall only be performed after final consultation with a medical doctor.

What is the recommended Whole-Body Hyperthermia (WBH) protocol for Essential Hypertension?

The protocol for Essential Hypertension recommends 12 sessions at a target temperature of 38.3 °C. Each session lasts approximately 45 minutes, comprising a 30-minute increase phase and a 15-minute resting phase (no plateau phase).

What are the recommended WBH parameters for Chronic Back Pain (Dorsalgia)?

For Dorsalgia, 6 sessions are typically recommended, targeting 38.4 °C. The total session time is approximately 90 minutes, with a 45-minute increase, a 15-minute plateau phase, and a 30-minute rest.

What is the WBH protocol for Fibromyalgia and Ankylosing Spondylitis?

Both Fibromyalgia and Ankylosing Spondylitis typically follow a 6-session protocol, targeting 38.5 °C. The total session time is about 90 minutes, including a 45-minute increase, a 15-minute plateau, and a 30-minute rest.

What is the recommended protocol for WBH as an Additive Cancer Treatment?

As an additive cancer treatment, the protocol requires 2 or more sessions targeting a core temperature between 39.0 °C and 40.0 °C. The total session time is the longest, ranging from 3 to 4 hours, which includes 60-90 minutes for the increase phase, 60-90 minutes for the plateau phase, and 60 minutes for the resting phase.

Indication Sessions Target Temp. Therapy (Increase + Plateau) Rest Time Total Session
Essential Hypertension 12 38.3 °C 30 min (30+0) 15 min ~ 45 min
Dorsalgia 6 38.4 °C 60 min (45+15) 30 min ~ 90 min
Fibromyalgia 6 38.5 °C 60 min (45+15) 30 min ~ 90 min
Ankylosing Spondylitis 6 38.5 °C 60 min (45+15) 30 min ~ 90 min
Systemic Sclerosis 15 38.3 °C 30 min (30+0) 15 min ~ 45 min
Major Depressive Disorder 1+ 38.5 °C 105-170 min 30 min ~ 2-3 hours
Additive Cancer Treatment 2+ 39.0-40.0 °C 120-180 min 60 min ~ 3-4 hours

NOTE: this article is not an exhaustive list of studies and effects of WBH wIRA

References and Citations

References

  1. Ardenne M. von. Moderate Hyperthermie als Behandlungsmethode mit vielen Indikationen. Ärztzeitschr Naturheilverf 1994; 5:356-61.
  2. Bäumler H., Scherf H.P., Aurisch R., et al. Einfluß einer Serie von Infrarot-Ganzkörperbestrahlungen auf Fließeigenschaften des Blutes und die Hämodynamik. Perfusion 1990: 138-43.
  3. Heckel M. Ganzkörper-Hyperthermie und Fiebertherapie, Grundlagen und Praxis. Stuttgart: Hippokrates Verlag, 1990.
  4. Kosaka M., Sugahara T., Schmidt K.L., Simon E. Thermotherapy: Principles and Practice. Heidelberg: Springer Verlag, 2000.
  5. Meffert H., Hecht H.C., Günther H., et al. Biophysikalische Ergebnisse des klinischen Tests der IRA-Therm-Hyperthermietechnik der 2. Generation. ThermoMed 1990; 6:71-78.
  6. Schmidt K.L. Hyperthermie und Fieber, Wirkungen bei Mensch und Tier. 2. überarb Aufl. Stuttgart: Hippokrates Verlag, 1987.
  7. Vaupel P., Krüger W. Wärmetherapie mit wassergefilterter Infrarot-A-Strahlung, Grundlagen und Anwendungsmöglichkeiten. 2. überarb Aufl. Stuttgart: Hippokrates Verlag, 1995.
  8. Piazena H., Meffert H. Optische Eigenschaften der Haut und die photobiologischen Grundlagen zur Dosierung von IR-Hautbestrahlungen in vivo und in vitro. 6. Symposium Licht und Gesundheit 2008.
  9. Zschaeck S. and Beck M. Chapter 8 Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?
  10. Zhang H, Wang W, Zhang S, Huang W. Comparison of the anti-tumor effects of various whole-body hyperthermia protocols… Immunol Invest. 2005;34(3):245-58.
  11. Abreu MM, Chocron AF, Smadja DM. From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy. Front Immunol. 2025 Feb 28;16:1487296.
  12. Bull JMC. et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-α. Journal of Hyperthermia. 2008; 24(8): 649-662.
  13. Weigelin B. Visualization of the immune effect of hyperthermia. ICHO 2021, Session: Hyperthermia and immunology.
  14. Faghihi Moghaddam F, Bakhshandeh M, Mofid B, et al. Clinical effectiveness of combined WBH and EBRT versus EBRT alone… J Therm Biol. 2024 Feb;120:103804.
  15. Hildebrandt B, Dräger J, Kerner T. et al. Whole-body hyperthermia in the scope of von Ardenne’s systemic cancer multistep therapy (sCMT)… International Journal of Hyperthermia. 2004;3:317–333.
  16. Atmaca A., Al-Batran S.E., Neumann A., et al. WBH in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study. Gynecol Oncol 2009; 2:384-88.
  17. Brockow T., et al. A Randomized Controlled Trial on the Effectiveness of Mild Water-filtered Near Infrared WBH… Clin J Pain 2007; 1:67-75.
  18. Kleef R, Nagy R, Baierl A, et al. Low-dose Ipilimumab plus Nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease. Cancer Immunol Immunother. 2021;70:1393–403.
  19. Adachi H., Katsuno M., Waza M., et al. Heat shock proteins in neurodegenerative diseases. Int J Hyperthermia 2009; 8:647-54.
  20. Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin… Gynecol Oncol 2009; 2:384-88.
  21. Bull J.M., et al. An Update of a Phase II Clinical Trial Using Fever-Range Whole-Body Thermal Therapy (FR-WB-TT)… Soc for Thermal Med, 2007.
  22. Bull J.M., et al. Fever-range WBH combined with cisplatin, gemcitabine and daily interferon-α. Int J Hyperthermia 2008; 8:649-62.
  23. Bull J.M., et al. A phase-I-study of optimally-timed Gemcitabine + Cisplatin/Interferon-a combined with WBH. ESHO 2001, Verona, Italy.
  24. Capitano M., Mace T., Nemeth M., et al. A novel strategy for improving neutrophil recovery following total body irradiation. Soc for Thermal Med, 2010.
  25. Dayanc B.E., Ostberg J.R., Repasky E.A. Enhancement of NK Cell Cytotoxic Activity by Mild Thermal Stress. Soc of Thermal Med, 2006.
  26. Hajto T., Hostanska K. Effect of in vivo hyperthermia on human natural killer cells. Clin Trials J 1985; 6:514-20.
  27. Hattori T., et al. Antitumor effect of WBH with α-galactosylceramide in a subcutaneous tumor model of colon cancer. Int J Hyperthermia 2007; 7:591-98.
  28. Kisailus A., et al. Thermal Regulation of Antigen Presenting Cells: Use of Hyperthermia as an Adjuvant for Cancer Vaccines. Soc of Thermal Med, 2006.
  29. Multhoff G. Activation of natural killer (NK) cells by heat shock protein 70… Int J Hyperthermia 2009; 3:176-79.
  30. Peer A.J., et al. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res 2010; 1-3:137-154.
  31. Rowe R.W., et al. Fever-range WBH combined with oxaliplatin: A curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia 2010; 6:565-76.
  32. Schencking M., Frese T., Sandholzer H. Behandlung einer Radikulopathie bei ossärer Metastasierung durch Infrarot-A-Ganzkörperhyperthermie. Forsch Komplementmed 2008; 15:273-76.
  33. Scott G.L., Bull J.M.C., Kochn M. Management of Conscious Sedation… 9th Int Congress on Hyperthermic Oncology, 2004.
  34. Shecterle L.M., Cyr J.A.S. Hyperthermia Aids Patients with Advanced Lung Cancer. Soc of Thermal Med, 2006.
  35. Skitzki J.J., Repasky E.A., Evans S.S. Hyperthermia as an immunotherapy strategy for cancer. Current Opinion in Investigational Drugs 2009; 6: 550-58.
  36. Toyota N., et al. Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis… Int. J. Hyperthermia 1997; 5:497-506.
  37. Wang X.Y., et al. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines… J of Immunology 2001; 165:490-97.
  38. VanderZee J., et al. Reirradiation combined with hyperthermia in breast cancer recurrences… Int J Hyperthermia 2010; 7:638-48.
  39. Zagar T.M., et al. Hyperthermia for locally advanced breast cancer. Int J Hyperthermia 2010; 7:618-24.
  40. Zagar T.M., et al. Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence… Int J Hyperthermia 2010; 7: 612–17.
  41. Sen A., Capitano M., Dommer M., et al. Thermoregulatory responses to mild systemic thermal stress increase tumor perfusion… Cancer Res. 2011; 71(11):3872-3880.
  42. Koska J., Rovensky J., Zimanova T., Vigas M. Growth hormone and prolactin responses during partial and whole body warm-water immersions. Acta Physiol Scand. 2003.
  43. Vigas M., Rovensky J., Zimanova T., Koska J. Responses of growth hormone and prolactin to local and whole-body application of Piestany mud. Acta Rheumatol 2002:31-38.
  44. Meffert B., Hochmuth O., Steiner M. Effects of multiple mild infrared-induced hyperthermia on central and peripheral pulse waves. North Sea Conference 1990.
  45. Meffert H., Scherf HP., Meffert B. Milde Infrarot-A-Hyperthermie. Auswirkungen von Serienbestrahlungen… Akt Dermatol 1993; 19:142-48.
  46. Applegate L.A., et al. Induction of the putative protein ferritin by infrared radiation: Implications in skin repair. Int J of Molecular Med 2000; 5:247-51.
  47. Scherf H.P., et al. Wirkung einer einmaligen milden Infrarot-A-Hyperthermie auf Körpertemperatur, Herzfrequenz, Blutdruck und Blutviskosität… Dermatol Monatsschr 1989.
  48. Streffer C. Metabolic changes during and after hyperthermia. Int J Hyperthermia 1985; 4:305-319.
  49. Förster J., et al. Infrared-Mediated Hyperthermia is Effective in the Treatment of Scleroderma-Associated Raynaud’s Phenomenon. J Invest Dermatol 2005.
  50. Koska J., Rovensky J., Zimanova T., et al. Sympathoadrenal regulation of circulatory responses to WBH… Acta Rheumatol 2002:23-30.
  51. Janssen C.W., et al. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder – A Randomized Clinical Trial. JAMA Psychiatry 2016.
  52. Tarner I.H., et al. The effect of mild WBH on systemic levels of TNF-alpha, IL-1 beta and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 2009.
  53. Ettrich U., et al. Milde Ganzkörperhyperthermie in Kombination mit stationärer multimodal orientierter Schmerztherapie… Orthopäde 2014; 2:165-74.
  54. Weller E., Ullrich D. Infrarot-A-Hyperthermie-Anwendung bei Patienten cu Analgetica-Abusus wegen chronischer Rückenschmerzen. 95. Kongreß Phys Med 1990.
  55. Morf S., Vesti B.A., Forster A., et al. Microcirculation abnormalities in patients with fibromyalgia – measured by capillary and laser fluxmetry. Arthritis Res Ther 2005.
  56. Walz J., et al. Ganzkörperhyperthermie in der Schmerztherapie – eine kontrollierte Studie an Patienten mit Fibromyalgiesyndrom. Schmerz 2013; 27:38-45.
  57. Romeyke T., Stummer H. Multi-modal pain therapy of fibromyalgia syndrome with integration of systemic WBH… J Musculoskel Pain 2014; 4:341-55.
  58. Zauner D., et al. WBH treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis. Int J Hyperthermia 2014.
  59. Lange U., et al. Wirkung iterativer Ganzkörperhyperthermie cu wassergefilterter Infrarot-A-Strahlung bei ankylosierender Spondylitis… Akt Rheumatol 2017.

EN: The complete database of over 60 clinical studies on wIRA technology is available upon request.

 

© Romanian Society Oncologic Hyperthermia All rights reserved. Source: Analysis based on scientific literature.